Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- befree-2016 importedOn "2016-02-19" NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion wasGeneratedBy ECO_0000203 NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion wasDerivedFrom befree-2016 NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion SIO_000772 22271575 NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion evidence source_evidence_literature NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
- NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.